Table 1 Clinical trial design
Characteristics | Number of patients |
|---|---|
Patients evaluable for response | 28 |
Patients evaluable for toxicity | 29 |
Sex | |
Male | 20 |
Female | 9 |
Performance status (ECOG) | 0–2 |
Primary site | |
Sigma and left colon | 21 |
Right colon | 8 |
Stage IV | 29 (100%) |
Disease extension | |
(A) Liver | 24 |
(B) No liver (bone+lung+peritoneum+ovary) | 5 |
Previous treatments | |
Surgery | 27 |
One line of chemotherapy | 20 |
Two or more lines of chemotherapy | 9 |
FUFA | 23 |
IFL | 7 |
FOLFOX-4 | 3 |
Raltitrexed | 1 |
Intra-hepatic mytomicin C infusion | 3 |
